|Bid||90.09 x 900|
|Ask||90.55 x 1100|
|Day's Range||90.21 - 91.53|
|52 Week Range||68.80 - 92.45|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||49.13|
|Earnings Date||Apr 14, 2020 - Apr 19, 2020|
|Forward Dividend & Yield||1.44 (1.59%)|
|Ex-Dividend Date||Jan 13, 2020|
|1y Target Est||100.15|
Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity™ Deep Brain Stimulation (DBS) system to include targeting of an area of the brain called the internal globus pallidus (GPi). The GPi plays an integral role in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories ...
ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2 system, is it time to buy Abbott stock?
Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.
The company posted full-year 2019 revenue of $31.9 billion, which was ahead of analyst projections and a 4.3% increase compared with 2018.
JP Morgan analyst Robbie Marcus said he expected 2020 to be another year of "top-tier growth" for Abbott, driven by strength from its glucose monitoring device, FreeStyle Libre, and its pipeline of heart devices. Abbott's Chief Operating Officer Robert Ford, a key person behind Libre's growth, will replace long-time Chief Executive Miles White in March and is expected to prioritize sales of the glucose monitoring device and heart device MitraClip.
Abbott Laboratories' incoming Chief Executive Officer Robert Ford said on Wednesday that deal-making was not on the company's agenda. "On the M&A side, we're not looking to do any deals right now," Ford, who currently serves as chief operating officer, said on a conference call. Ford also noted that Abbott intended to raise dividend payments to shareholders.
ABT stock rose higher in a buy zone Wednesday after the medical technology company beat Wall Street's fourth-quarter revenue expectations and issued strong 2020 sales guidance.
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Abbott Laboratories were up 1% after the company reported sales increases across each of its four businesses in the fourth quarter of 2019. Net earnings were $1.05 billion, or 59 cents per share, in the fourth quarter, up from $654 million, or 37 cents per share, in the same quarter a year ago. Abbott said that adjusted earnings per share were $0.95 per share, compared with the FactSet consensus of $0.95. Total sales were up 7.1% to $8.3 billion, compared with the FactSet consensus of $8.2 billion. Medical device sales increased 9.7%, nutrition sales rose 5.2%, pharmaceutical sales were up 7.8%, and laboratory diagnostics sales rose by 8.4%. Sales of the company's MitraClip device, which is used in minimally invasive cardiovascular procedures, jumped 27% to $191 million. Abbott said it expects adjusted EPS of $3.55 to $3.65 in 2020. The FactSet consensus is $3.61. Abbott's stock has gained 25% over the last year. The SPDR Health Care Select Sector exchange-traded fund is up 16%, while the Dow Jones Industrial Average has gained about 18%.
Stocks rise as China moves swiftly to limit the spread of the deadly coronavirus. IBM lifts the Dow after an earnings beat.
Investing.com - Abbott Labs reported on Wednesday fourth quarter earnings that matched analysts' forecasts and revenue that topped expectations.
On Wednesday, January 22, Abbott Laboratories (NYSE: ABT ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Wall Street analysts see Abbott ...
Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain drugs, a few clinical data readouts, presentations and updates at the ...
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Seven years ago, the two big China tech giants introduced mobile payments for the exchange of cash gifts—so-called red envelopes. Now the pair continue to compete to increase and engage users.